Get started
Author

Inge C.F.M. Roozen

Observed names: I. Roozen, Inge C F M Roozen, Inge C. Roozen, Inge Roozen
Observed institution: Leiden University Medical Center
ORCID: 0009-0006-1352-5684
Observed ORCID: 0009-0006-1352-5684
OpenAlex ID: A5041980286
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.
2014 · Sophie Piperno-Neumann, Ellen Kapiteijn, et al. · Journal of Clinical Oncology · 58
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
2022 · Frank M Speetjens, Marij J P Welters, et al. · Journal for ImmunoTherapy of Cancer · 42
PDF
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
2023 · Els M E Verdegaal, Saskia J Santegoets, et al. · Journal for ImmunoTherapy of Cancer · 30
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
2020 · Els Verdegaal, Monique K van der Kooij, et al. · Journal for ImmunoTherapy of Cancer · 29
PDF
Landscape of genetic alterations in patients with metastatic uveal melanoma.
2014 · Sophie Piperno-Neumann, Ellen Kapiteijn, et al. · Journal of Clinical Oncology · 18
A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.
2016 · Marije Slingerland, Frank Speetjens, et al. · Journal of Clinical Oncology · 14
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial
2020 · Monique K van der Kooij, Els M E Verdegaal, et al. · BMJ Open · 10
PDF
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial
2026 · Linde van den Hoek, Mark Burgmans, et al. · The Lancet Oncology · 9
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al. · Clinical Cancer Research · 6
Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.
2021 · Frank M. Speetjens, Marij JP Welters, et al. · Journal of Clinical Oncology · 3
729P Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)
2021 · J.R. Kroep, M. Visser, et al. · Annals of Oncology · 2
PDF
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
2022 · Thaïs M.L. Tong, Mark C. Burgmans, et al. · Journal of Clinical Oncology · 1
Data from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Figure S6 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S4 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S2 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S5 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Table S2 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Figure S3 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S1 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Table S1 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S4 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S5 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S3 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PO008/#393 Timed adoptive T-cell therapy during chemotherapy in platinum sensitive recurrent epithelial ovarian cancer, the ovacure phase I/II trial
2023 · Judith Kroep, Linda De Bruin, et al. · International Journal of Gynecological Cancer
PDF
Works count: 28
Citation count: 222
H-index: 8
I10-index: 7
Year
Topic
Type